Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.395,84
-0,78%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ MoonLake Immunotherapeutics (MLTX) MoonLake Immunotherapeutics (MLTX) Notizie

MoonLake Immunotherapeutics

MLTX
45,26
2,69 (6,32%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/4/202413:00BWMoonLake Immunotherapeutics Inks Three-Year Technology..
11/3/202413:01EDGAR2Form 8-K - Current report
10/3/202417:00GLOBEMoonLake announces significant improvements with Nanobody®..
04/3/202414:00GLOBEMoonLake Immunotherapeutics to present MIRA trial data of..
01/3/202401:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202401:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202414:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202414:03EDGAR2Form 8-K - Current report
29/2/202414:00GLOBEMoonLake Immunotherapeutics Reports Full Year 2023 Financial..
26/2/202415:00EDGAR2Form 8-K - Current report
26/2/202414:00GLOBEMoonLake Immunotherapeutics Announces Positive Feedback from..
23/2/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202400:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:02EDGAR2Form 144 - Report of proposed sale of securities
15/2/202414:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:05EDGAR2Form 144 - Report of proposed sale of securities
21/12/202322:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:16EDGAR2Form 144 - Report of proposed sale of securities
19/12/202322:34EDGAR2Form 144 - Report of proposed sale of securities
14/11/202314:00GLOBEMoonLake Immunotherapeutics Reports Third Quarter 2023..
06/11/202313:55EDGAR2Form 8-K - Current report
05/11/202317:00GLOBEMoonLake Immunotherapeutics announces landmark Phase 2..
16/10/202312:16EDGAR2Form 8-K - Current report
15/10/202315:03GLOBEMoonLake Immunotherapeutics announces the full dataset from..
11/10/202316:15GLOBEMoonLake Immunotherapeutics presents positive 12-week data..
04/10/202313:01GLOBEPhase 2 MIRA primary analysis trial results (12-week) for..
06/9/202313:00GLOBEMoonLake Immunotherapeutics to host a Capital Markets Day on..
10/8/202313:00GLOBEMoonLake Immunotherapeutics Reports Second Quarter 2023..
25/7/202314:00GLOBEMoonLake completes patient randomization ahead of schedule..
17/7/202313:30IHMARKETNEWSMonday’s Wall Street Highlights: Microsoft, Santander,..
28/6/202311:00GLOBEMoonLake Immunotherapeutics Announces Pricing of $400..
26/6/202322:01GLOBEMoonLake Immunotherapeutics Announces Proposed Underwritten..
25/6/202315:00GLOBEMoonLake Immunotherapeutics achieves landmark milestone with..
12/5/202313:45GLOBEMoonLake Immunotherapeutics Reports First Quarter 2023..
Apertura: 43,51 Min: 43,405 Max: 45,465
Chiusura: 42,57

La tua Cronologia

NASDAQ
MLTX
MoonLake Immunotherapeut...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network